InMed Pharmaceuticals (INM) Registration filing summary

Company overview and business model

• Develops proprietary small molecule drug candidates targeting CB1 and CB2 receptors for diseases with high unmet medical needs.

• Focuses on pharmaceutical R&D, leveraging the endocannabinoid system for therapeutic applications.

• Incorporated in British Columbia, Canada, with a history of executive and business sector changes since 1981.

Financial performance and metrics

• Aggregate market value of common stock held by non-affiliates is approximately $2.6 million as of March 18, 2026.

• Audit reports highlight recurring losses, negative cash flows, and an accumulated deficit, raising substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including working capital, operating expenses, and capital expenditures.

• May use proceeds to repay debt or acquire/invest in complementary businesses, products, or technologies, though no current commitments exist.

• Unallocated funds may be invested in marketable securities and short-term investments.